{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF00071",
      "entity_text" : "Ras",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:446013",
      "entity_text" : "FDA",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "However, there is little understanding of the factors leading to the isoform specific preferences associated with Ras oncogenic mutants, and, in spite of great need, there are no US Food and Drug Administration (FDA)-approved inhibitors of Ras available in the clinic.",
  "reading_complete" : "2020-08-08T16:18:15Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T16:12:22Z",
  "trigger" : "inhibitors",
  "evidence" : [ "FDA)-approved inhibitors of Ras" ],
  "pmc_id" : "6709685",
  "score" : 0
}